Trillium Therapeutics Inc.
Trillium Therapeutics Inc. (TRIL): 2 pipeline candidates · ~53 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
52.9 months
D/E 0.09 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Trillium Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$93.2M
Quarterly Burn
$14.0M
Runway
52.9 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Trillium Therapeutics Inc.'s pipeline?
Trillium Therapeutics Inc. (TRIL) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Trillium Therapeutics Inc.'s lead drug candidate?
Trillium Therapeutics Inc.'s most advanced tracked candidate is tti-621 (Phase 1) for advanced relapsed or refractory hematologic malignancies, including CTCL.
What is Trillium Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Trillium Therapeutics Inc. has approximately 52.9 months of cash runway.
Who is the CEO of Trillium Therapeutics Inc.?
Jan Skvarka is the chief executive officer of Trillium Therapeutics Inc. (TRIL).
Get the full picture on Trillium Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.